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A limited number of reports have investigated the role of microRNAs in osteosarcoma. In this study, we performed miRNA
expressionproﬁlingofosteosarcomacelllines,tumorsamples,andnormalhumanosteoblasts.Twenty-twodiﬀerentiallyexpressed
microRNAs were identiﬁed using high throughput real-time PCR analysis, and 4 (miR-135b, miR-150, miR-542-5p, and miR-652)
were conﬁrmed and validated in a diﬀerent group of tumors. Both miR-135b and miR-150 have been previously shown to be
important in cancer. We hypothesize that dysregulation of diﬀerentially expressed microRNAs may contribute to tumorigenesis.
They might also represent molecular biomarkers or targets for drug development in osteosarcoma.
1.Introduction
Osteosarcomaisthemostcommonmalignantbonetumorin
childhood and adolescence. Although many tumors initially
respond to chemotherapy, patients with metastatic disease
and/or relapsed disease continue to have extremely poor
survival outcomes [1]. A better understanding of osteosar-
coma biology is needed to further optimize treatment
strategies, biomarker identiﬁcation, and the development
of new chemotherapeutic agents. Previous studies have
demonstrated diverse genetic alterations in osteosarcoma
cells, including structural abnormalities, gains and/or losses
of chromosomes, as well as mutations in tumor suppres-
sor genes [2]. Epigenetic modiﬁcations such as genomic
DNA methylation and alterations of chromatin-associated
proteins have also been implicated in osteosarcoma car-
cinogenesis [3, 4]. However, the role of noncoding RNAs,
especially microRNAs, in the initiation and progression of
osteosarcoma is yet to be elucidated.
MicroRNAs (miRNAs) are small noncoding RNAs that
can regulate gene expression by blocking mRNA translation
and/or aﬀecting mRNA stability within cells [5]. In the last
few years, there has been growing evidence that miRNAs are
key regulators in the cells; a single miRNA can aﬀect the
expression of hundreds of protein coding target genes [6].
Dysregulated miRNA expression has been demonstrated in
many human disease states, including cancer. Up- and/or
downregulation of miRNA expression in cancer suggest that
miRNAs can function as classical tumor suppressor genes or
oncogenes [7, 8]. Further, miRNAs have been implicated in
the development of tumor metastasis [9]. Though previous
publicationshaveexploredtheroleofmiRNAsinmanyadult
and pediatric cancers, there is limited understanding of their
role in osteosarcoma.
A study of osteosarcoma cell lines and primary tumor
samples revealed an interaction between miR-34 and p53;
tumor samples showed a decreased expression of miR-34
and inhibited p53-mediated cell cycle arrest and apop-
tosis [10]. In another study using osteosarcoma cells in
a mouse xenograft model, increased miR-140 expression
was associated with chemoresistance [11]. The same group
recently reported that miR-215 conferred chemoresistance to2 Sarcoma
methotrexate in osteosarcoma cells in vitro by suppression
of a cell cycle-regulated nuclear and centrosome protein
[12]. In a study using 8 paired tumor and normal tissue
samples as well as the osteosarcoma cell line MG-63, Ziyan
et al. demonstrated upregulation of miR-21 (a well-known
oncomiR in other tumor types) in osteosarcoma [13].
Knockdown of miR-21 in the cell line resulted in decreased
cell invasion and migration [13]. Another group identiﬁed a
proapoptotic function of miR-143 through downregulation
of Bcl-2 expression in osteosarcoma cell lines and primary
tumor samples [14].
The goal of this study was to identify diﬀerentially
expressed miRNAs in osteosarcoma cell lines and tumor
samples.Wescreened762maturemiRNAsin2osteosarcoma
cell lines and 4 formalin-ﬁxed paraﬃn-embedded (FFPE)
osteosarcoma samples. We have conﬁrmed the expression of
selected miRNAs using real-time quantitative PCR (RT Q-
PCR) in the initial samples and validated the ﬁndings in
3 additional FFPE tumors. These ﬁndings provided some
insights into the role of miRNAs in osteosarcoma and might
be of importance for the identiﬁcation of new biomarkers
and future drug design.
2.MaterialsandMethods
2.1. Patient Samples. After approval by the Institutional
Review Board (IRB) at Children’s Memorial Hospital, a total
of 10 primary nondecalciﬁed FFPE blocks were obtained
from pediatric patients with osteosarcoma treated at our
institution between 1997 and 2010. In all cases, the ﬁnal
pathologic diagnosis was conventional osteoblastic osteosar-
coma and the patients had no previous treatment with
chemotherapy. From each tumor block, a representative H
& E slide was prepared and 5– 20-µm thick sections were cut
and provided for further analysis.
2.2. Cell Culture. Two human osteosarcoma cell lines—HOS
(ATCC no. CRL-1543) and 143B (ATCC no. CRL-8303)—
were obtained from American Type Culture Collection
(Manassas, Va). The cells were cultured and maintained
at 37◦Ci n5 %C O 2 in Eagle’s Minimum Essential Medi-
um containing 10% heat-inactivated fetal bovine serum
and 5% penicillin/streptomycin (Invitrogen, Carlsbad,
Calif). A normal human osteoblast cell line, HOB (C-
12720), was obtained and grown in Osteoblast Growth Me-
dium (PromoCell, Heidelberg, Germany). In an at-
tempt to minimize the diﬀerence between the human
tissues and control osteoblasts, HOB cells were pel-
leted, ﬁxed in formalin, and embedded in paraﬃnp r i o r
to RNA extraction as previously described (http://web
.ncifcrf.gov/rtp/lasp/phl/immunohistochemistry.asp).
2.3. RNA Extraction. RNA puriﬁcation of FFPE samples was
performed using RecoverAll Total Nucleic Acid Isolation
system (Ambion, Austin, Tex) according to the manufac-
turer’s instructions. In all the sections provided by the
pathology department as well as the embedded HOB cells,
tumor areas were carefully macrodissected using a scalpel
and transferred into a 1.5-mL centrifuge tube. Paraﬃnw a s
removed by 100% xylene at 50◦Cf o r3m i n .T h et u b ew a s
centrifuged, xylene was discarded, and the pellet was washed
twice with 100% ethanol followed by air drying. The pellet
was digested by protease at 50◦C for 15 minutes, and at 80◦C
for 15 minutes and RNA was puriﬁed with ﬁlter cartridges.
Total RNA of the cell lines (HOS and 143B) was extracted
using TRIzol (Invitrogen) according to the manufacturer’s
instructions. RNA quality and quantity was determined
usingaNanoDropND-1000spectrophotometer(NanoDrop,
Wilmington, Del). Of the 10 samples obtained, 7 had high-
qualityRNAandwereusedforfurtheranalysis.Foursamples
were used in the initial miRNA proﬁling experiments, and 3
were used for validation of the ﬁndings.
2.4.miRNAExpressionProﬁlingofCellLinesandInitialTumor
Samples. TaqMan miRNA assays were used to quantify
the levels of 762 mature miRNAs in osteosarcoma cell
lines, normal human osteoblasts, and 4 tumor samples as
described previously [15, 16]. Experimental replicates were
performed for all cell lines. Each reverse transcriptase (RT)
reaction contained puriﬁed total RNA and the TaqMan
MicroRNA Megaplex Reverse Transcription Kit (Applied
Biosystems, Foster City, Calif) prepared according to the
manufacturer’s instructions. The reactions were incubated
for 30min at 16◦C, 30min at 42◦C, and 5min at 85◦C.
The resulting cDNA was then preampliﬁed using Megaplex
PreAmp Primers according to manufacturer’s instructions.
Real-time PCR reactions for each miRNA were performed in
a 900-¯L reaction mixture that included 9¯L of diluted and
preampliﬁed RT product, 450-¯L of 2X TaqMan Universal
PCR Master Mix, No AmpErase UNG (Applied Biosystems),
and 441-¯L of nuclease free water. Reactions were incubated
in an Applied Biosystems 7900HT Fast Real-Time PCR
system in 384-well low-density arrays (TLDAs) at 94.5◦Cf o r
10min, followed by 40 cycles at 97◦C for 30s and 60◦Cf o r
1min.
2.5. Conﬁrmation and Validation of Individual miRNAs.
After the initial screening, 4 diﬀerentially expressed miRNAs
were selected, and total RNA was puriﬁed from cell lines and
the initial 4 tumor samples and was used to perform individ-
ual miRNA assays. Each reverse transcriptase (RT) reaction
contained total RNA and the TaqMan Individual MicroRNA
Reverse Transcription Primer (Applied Biosystems), pre-
pared according to the manufacturer’s instructions. The
reactions were performed as described in Section 2.4.
Real-timePCRreactionsforeachindividualmiRNAwere
performed in a 20-¯L reaction mixture that included 1.33-
¯L of diluted RT product, 1-¯L of 20C TaqMan Individual
microRNAassay,10-uLof2XTaqManUniversalPCRMaster
Mix, No AmpErase UNG (Applied Biosystems) and 7.67-
¯L of nuclease free water. Reactions were incubated in
triplicate on an Applied Biosystems 7900HT Fast Real-
Time PCR system in 96-well plates in the PCR conditions
described above. Expression levels of the selected miRNAs
were then validated in total RNA from three additionalSarcoma 3
tumor samples that had not previously been tested using the
same methodology described here.
2.6. Statistical Analysis. Data from miRNA proﬁling experi-
ments was analyzed using the RealTime StatMiner software
(Version 4.0, Integromics). The negative Ct values of all
miRNA probes were median centered by sample and then
normalized against the endogenous control Mammalian
U6. The expression values were subjected to hierarchical
clustering by Pearson’s correlation by using Multiexperiment
Viewer (Version 4.5.1, http://www.tm4.org/mev/). For indi-
vidual assay conﬁrmation and validations, Student’s t-tests
were used to assess the statistical signiﬁcance between the
relative miRNA expression between tumors and control. For
all analyses, a two-tailed value of P<0.05 was considered
signiﬁcant.
3. Results
3.1.DiﬀerentialExpressionofmiRNAsinOsteosarcoma. Real-
timeqPCRwasusedtoevaluatetherelativeexpressionof762
mature miRNA expression levels in 4 human tumors and 2
osteosarcoma cell lines (HOS and 143B) compared to a nor-
mal human osteoblast cell line (HOB). Unsupervised hierar-
chical clustering was performed using the relative expression
values for all samples and all miRNA probes. Based on their
expression values, each group (normal osteoblasts, human
tumors, and osteosarcoma cell lines) clustered together, thus
conﬁrming similar miRNA expression proﬁles (Figure 1).
Additionally, the tumor samples and osteosarcoma cell lines
clusteredindependentlyfromthenormalhumanosteoblasts.
3.2. Pairwise Comparison of Test Groups. RealTime Stat-
Miner software was used to compare the expression proﬁles
between human tumors and normal human osteoblasts.
This analysis revealed 22 signiﬁcantly diﬀerentially expressed
miRNAs (P<0.05) (Table 1). Two additional comparisons
weredone.Osteosarcomacelllineswerecomparedtonormal
osteoblasts, and 5 individual miRNAs that matched those in
the original list were identiﬁed. Finally, osteosarcoma cell
lines and human tumors were compared, and 14 out of
the 22 previously identiﬁed miRNAs exhibited statistically
signiﬁcant diﬀerential expression.
3.3. Selection of Candidate miRNAs for Validation. Of the 22
miRNAs initially identiﬁed, 4 were selected for individual
conﬁrmation (miR-135b, miR-150, miR-542-5p and miR-
652) based upon the fact that they were diﬀerentially
expressed in both comparisons of human tumor and
osteosarcoma cell lines when compared to osteoblasts.
Furthermore, 3 of these candidates (miR-135b, miR-542-
5p, and miR-652) had no expression in tumor samples and
osteosarcoma cell lines, which minimizes the likelihood that
expression diﬀerences are a result of diﬀerences between
immortalized cell lines and heterogeneous tumor samples.
Despite the veriﬁed diﬀerence in expression of miR-150
comparing tumors and cell lines, this candidate miRNA
was selected for validation given the amplitude of expres-
sion diﬀerences observed when tumors were compared to
osteoblasts.
3.4. Conﬁrmation of Candidate miRNAs in the Original Sam-
ples. IndividualmiRNAassayswereperformedontotalRNA
from the initial tumor samples to determine the expression
levelsofmiR-135b,miR-150,miR-452-5pandmiR-652when
compared to normal human osteoblasts. All 4 miRNAs
were overexpressed in tumors when compared to normal
osteoblasts as shown in Table 2.
3.5. Validation of Candidate miRNAs in the Test Samples.
Total RNA from three additional tumor samples that had
notpreviouslybeenanalyzedwasusedforindividualmiRNA
assays of the 4 candidate miRNAs. For all 4 probes, the
miRNAs were overexpressed when compared to normal
human osteoblasts in a similar pattern to that of the ﬁrst 4
tumors samples. The expression levels for all 7 samples are
shown in Figure 2.
4. Discussion
With the objective of identifying miRNAs that are important
in osteosarcoma tumorigenesis, we have performed miRNA
expression proﬁling of two osteosarcoma cells lines as well
as 4 FFPE human tumor samples using TLDA arrays. We
proﬁled 762 miRNAs and identiﬁed 22 that are diﬀerentially
expressed in osteosarcoma (Table 1). Furthermore, we have
conﬁrmed and validated 4 candidate miRNAs in the initial
cohort of tumor samples, and in a test set of 3 additional
tumor samples. To our knowledge, our study is among the
ﬁrst to perform TaqMan array based miRNA proﬁling in
osteosarcoma samples using FFPE samples.
I no u rs t u d y ,w ew e r ea b l et or e l i a b l ye x t r a c tm i R N A s
from FFPE tissues of human osteosarcoma. Several groups
have already discussed the utility and reliability of using
FFPE samples for microRNA expression analyses [17, 18].
One of the barriers for basic research in osteosarcoma
is the fact that most tumor tissues are decalciﬁed prior
to histological analyses; as a result, the nucleic acids are
degraded. However, we were able to successfully perform
our analyses on nondecalciﬁed tumor blocks obtained from
primary biopsies.
In the tumor samples used in our study, miR-135b was
one of the miRs found to be signiﬁcantly overexpressed in
human osteosarcoma when compared to normal osteoblasts.
Recently, expression proﬁling studies in both colon cancer
and prostate cancer have shown consistent overexpression of
miR-135b in aﬀected tissues [19, 20]. Additionally, a recent
study has demonstrated that low levels of miR-135b are
important for the normal development and mineralization
of osteoblasts. Overexpression of miR-135b resulted in
abnormal mineralization, and diﬀerentiation of unrestricted
somatic stem cells [21]. We hypothesize that high levels of
miR-135b may inhibit normal diﬀerentiation of stem cells
into osteoblasts and this might explain the abnormal growth4 Sarcoma
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Figure 1: Heat Map showing unsupervised hierarchical clustering performed using Pearson’s correlation (Multiexperiment Viewer, Version
4.5.1). Relative expression values from normal osteoblasts (HOB), 2 osteosarcoma cell lines (HOS and 143B), and 4 human tumors samples
(OS 1, 2, 3, and 5) are represented in the main tree (a). A higher magniﬁcation of the column dendrogram showing that each group clusters
together suggesting that the samples have similar miRNA expression proﬁles (b).
Table 1: Fold change diﬀerences from 22 miRNAs comparing human tumor samples, osteosarcoma cell lines, and normal osteoblasts.
miRNA Tumors versus control∗ C e l ll i n e sv e r s u sc o n t r o l ∗ Tumors versus cell lines∗
hsa-miR-126 652.38 65.02
hsa-miR-135b 286.45 137.51
hsa-miR-140-3p 116.06 43.17
hsa-miR-140-5p 19.91 87.88
hsa-miR-142-3p 3103.47 3589.12
hsa-miR-148a 23.30 115.05
hsa-miR-150 15660.58 88.72 176.50
hsa-miR-18a 88.84
hsa-miR-194 583.46 63.78
hsa-miR-198 −33.11 −714.28 21.00
hsa-miR-200b 230.73
hsa-miR-210 2340.79 52.98
hsa-miR-223 215.02 27387.46
hsa-miR-301b 71.53
hsa-miR-450a 389.49 18.64
hsa-miR-451 601.47
hsa-miR-454 97.52
hsa-miR-455 1433.78 68.88
hsa-miR-511 185.41 384.98
hsa-miR-542-5p 497.64 62.86
hsa-miR-652 348.87 458.92
hsa-miR-660 67.65 39.31
∗P ≤ 0.05 for all comparisons.
of osteosarcoma cells. However, further analyses exploring
the targets of miR-135b are warranted.
Other groups have already shown that the expression
of miR-150, a hematopoietic speciﬁc miRNA, is important
in the diﬀerentiation of B and T lymphocytes in normal
hematopoiesis [22]. The aberrant expression of miR-150 in
solid tumors has been recently explored by Wu et al., and
they reported high levels of miR-150 in gastric cancer tissues.
This analysis has conﬁrmed that overexpression of miR-
150 is able to promote gastric cancer proliferation both in
vitro and in vivo [23]. In our study, we have identiﬁed a
nearly 50-fold overexpression of miR-150 in osteosarcoma
samples when compared to normal osteoblasts. Importantly,
the proapoptotic EGR2 (early growth response 2) and the
P2X7receptorhavebeenconﬁrmedasthetargetsofmiR-150
[23,24].TheP2X7receptorisinvolvedinsignaltransductionSarcoma 5
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Figure 2: Overexpression of selected miRNAs in osteosarcoma
tumor samples. Individual miRNA assays were performed with the
4initialsamplesconﬁrmingthediﬀerentialexpressionof4miRNAs
that were identiﬁed when compared to normal osteoblasts in the
ﬁrst screening. A “test set” comprising of three additional tumors
was used to further validate these ﬁndings.
Table 2: Mean expression fold changes of candidate miRNAs in 7
human tumors as compared to normal osteoblasts.
miRNA Average fold change Standard deviation
hsa-miR-135b∗ ≥20.88 14.81
hsa-miR-150 44.77 16.50
hsa-miR-542-5p 9.47 6.77
hsa-miR-652 8.00 3.33
∗No miR-135b was detected in the control osteoblasts.
and has been well characterized as a promoter of apoptosis
in both osteoblasts and osteoclasts [25]. Based on these
analyses and the results presented here, we hypothesize
that upregulation of miR-150 may downregulate the P2X7
receptor resulting in uncontrolled growth of osteosarcoma
cells.
The two other microRNAs that were overexpressed and
conﬁrmed in this study, miR-542-5p and miR-652, have only
a few reports in the literature. Recently, a group has reported
the association of miR-542-5p overexpression in favorable
histology, MYCN nonampliﬁed neuroblastoma samples [26,
27]. No data are available in the literature regarding miR-
652 and cancer thus far; however, bioinformatic predictions
suggest that this miRNA has more than 800 potential gene
targets. The ﬁndings of our study with regard to miR-
542-4p and miR-652 will require further investigation in
osteosarcoma.
Results of our miRNA proﬁling experiments revealed
22 diﬀerentially expressed miRNAs. Given the scope of this
study, validation was only done for 4 individual miRNAs.
However, many of the other identiﬁed miRNAs may be
important in osteosarcoma tumorigenesis. One such exam-
ple is miR-210, which was found to be signiﬁcantly elevated
in our tumor samples and it has been well studied in other
cancers. miR-210 is a key player in the hypoxic response, and
it has been found to be upregulated in all cell types tested
thus far in hypoxic conditions [28]. Recently, miR-210 was
foundtobeapositiveregulatorofosteoblasticdiﬀerentiation
through inhibition of AcvR1b (activin A receptor type 1B)
[29]. Given the ﬁndings of this study, the role of miR-210 in
osteosarcoma should be further investigated.
The results of our study share some similarities with a
paper recently published by Maire et al. in which miRNA
expressionpatternsinfrozenosteosarcomatumorspecimens
were compared with osteoblasts. Further, gene expression
data on the same specimens was also used to explore
mechanisms of miRNA deregulation in osteosarcoma [30].
Amongst others, the authors report overexpression of miR-
126, miR-142-3p and miR-451 as was also shown in
our data (Table 1). In some cases, miRNA-overexpression
corresponded to gains in the miRNA coding sequences in
areas of known chromosomal alterations in osteosarcoma.
Additionally, several underexpressed miRNAs were also
reported [30]. Taken together with our data, this suggests a
critical role for miRNA expression with and without DNA
copy alterations in osteosarcoma.
Our study has some limitations that warrant discussion.
The number of patient samples is low with only 7 of the 10
samples containing RNA suitable for analysis. The remaining
3 samples had a signiﬁcant amount of necrosis on the
representative H&E section, which likely explained the poor
RNA quality. Conﬁrmation of these ﬁndings in a larger
cohort of tumor samples would be of importance. We also
acknowledgethatthenormalcontrolselectedforthisstudyis
a normal adult human osteoblasts cell line. Though some of
the miRNA diﬀerences may be inherent diﬀerences between
cell lines and human tissue, we attempted to minimize
this confounder by simultaneously using tumor cells lines
as well as tissue samples to choose candidate miRNAs for
conﬁrmation.Forfuturestudies,pediatricosteoblastsand/or
sections of normal bone enriched for osteoblasts should be
considered as normal controls.
In conclusion, our study is one of the ﬁrst to use
osteosarcoma samples in FFPE to perform miRNA expres-
sion analysis by TaqMan Real-Time PCR in large scale and
to compare them to normal human osteoblasts. Using this
strategy, we were able to identify twenty-two diﬀerentially
expressed microRNAs, and 4 (miR-135b, miR-150, miR-
542-5p and miR-652) were selected for individual conﬁr-
mations. Overexpression of the selected candidate miRNAs
was further validated in 3 additional tumor FFPE samples.
In our samples, miR-135b was signiﬁcantly overexpressed,
and it has already been shown to have a role in normal
osteoblastic diﬀerentiation; high levels of miR-135b result
in abnormal mineralization. Additionally, miR-150 may
contribute to osteosarcoma tumorigenesis by inhibition of
proapoptoticgenesasshowninothercancers.Finally,several
other diﬀerentially expressed microRNAs were uncovered in
our study (e.g., miR-210) and warrant further evaluation in
osteosarcoma tumorigenesis.
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